Specialised management of OAB: sacral neuromodulation or Botulinum toxin A injection: What’s the best treatment for which patient?
The aim of this webinar is to provide elements based on literature and experts’ experience to guide the choice between sacral neuromodulation or Botulinum toxin A injection in patients suffering from idiopathic refractory OAB.
| Organiser | ESU |
|---|---|
| CME | 1 |
| Duration | Approx. 60 minutes |
First, comments will be given on current guidelines on OAB management. Then, strengths and weaknesses of both therapies will be exposed including a critical review of the Rosetta study and long-term results (outcomes of both therapies and discontinuation rate of botulinum toxin A injection). Finally an interactive case will be presented in order to illustrate everyday practice. The objective is to help participants optimise OAB management.